Effects of Statin Therapy on Vascular Properties and Outcomes in Diastolic Heart Failure Patients

Inclusion Criteria: * Signed informed consent, * Age \> 18, * Ejection fraction ≥ 50%, * hospitalization for heart failure in the last 6 months and * current NYHA Class II-IV symptoms, OR * current NYHA Class III-IV symptoms and one of the following: 1. ECG or echocardiographic evidence of moderate/severe left ventricular hypertrophy, 2. chest x-ray evidence of pulmonary congestion Exclusion Criteria: * Probable alternative cause of symptoms (pulmonary disease, severe anemia, etc.) * Prior documented LVEF \< 40% or qualitative moderate or greater LV systolic dysfunction. * Current indication for statin therapy * Intolerance to statin therapy. * Documented ischemic heart disease requiring lipid-lowering therapy (i.e. CAD, myocardial infarction, stroke) * Evidence of significant myocardial ischemia on stress testing at screening visit. * Evidence of hepatic abnormality (defined as liver enzymes \> 2 times the upper limit of normal values). * Uncontrolled hypertension (BP \> 150/100) * Significant valvular disease. * Atrial fibrillation * Known familial hypertrophic cardiomyopathy or obstructive hypertrophic cardiomyopathy. * Restrictive cardiomyopathy or systemic illness known to be associated with infiltrative heart disease (i.e. amyloidosis, sarcoidosis, hemochromatosis). * Cor pulmonale or other cause of right heart failure not related to LV dysfunction. * Clinically significant pulmonary disease. * Pericardial constriction or hemodynamically significant pleural effusion. * Uncontrolled arrhythmia. * Any systemic condition other than heart failure that may limit survival to less than 2 years. * Advance renal disease (serum creatinine \> 3.0 mg/dl or on dialysis) * Known intolerance or allergy to HMG CoA reductase inhibitors * Uncontrolled hyper- or hypothyroidism. * Any subject characteristic that may interfere with study compliance, such as baseline dementia, substance abuse, history of non-compliance with medications or appointments. * Prisoners or other vulnerable populations. * Any woman of child-bearing age with a documented positive pregnancy test. * Subject is receiving therapy with other investigational therapy or is participating in any other clinical trial.